DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma

• Shangzi Wang,
• Elana J Fertig,
• Allison A Fitzgerald,
• Veena Agarwal,
• Emily F Marcisak,
• Annie Zuo,
• Sandra A Jablonski,
• Melanie Loth,
• John MacDougall,
• Eugene Zhukovsky,
• Shubhendu Trivedi,
• Dimple Bhatia,
• Vince O'Neill,
• Louis M Weiner

Affiliations

Shangzi Wang

Aff498 grid.213910.80000000119551644Georgetown Lombardi Comprehensive Cancer Center Washington DC USA

Elana J Fertig

Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Allison A Fitzgerald

Department of Oncology, Georgetown University Medical Center, Washington, DC, USA

Veena Agarwal

Immune-oncology, BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Emily F Marcisak

McKusick-Nathans Institute of the Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Annie Zuo

Department of Oncology, Georgetown University Medical Center, Washington, DC, USA

Sandra A Jablonski

Department of Oncology, Georgetown University Medical Center, Washington, DC, USA

Melanie Loth

McKusick-Nathans Institute of the Department of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

John MacDougall

Totus Medicines, Cambridge, Massachusetts, USA

Eugene Zhukovsky

BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Shubhendu Trivedi

BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Dimple Bhatia

BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Vince O'Neill

BioXcel Therapeutics Inc, New Haven, Connecticut, USA

Louis M Weiner

Department of Oncology, Georgetown University Medical Center, Washington, DC, USA